Article

Lithium Treatment Reduces Suicide Risk in Recurrent Major Depressive Disorder

Harvard University, Cambridge, Massachusetts, United States
The Journal of Clinical Psychiatry (Impact Factor: 5.5). 04/2007; 68(3):380-3. DOI: 10.4088/JCP.v68n0304
Source: PubMed

ABSTRACT

Evidence that clinical treatment reduces suicide risk in major depressive disorder (MDD) is limited and inconsistent. Since lithium shows major antisuicidal effects in bipolar disorders and in heterogeneous mood disorder samples, we evaluated evidence of antisuicidal effects of lithium in patients with recurrent MDD.
We searched MEDLINE (January 1966 to April 2006; search terms: lithium, suicide, affective disorder, depression, major depression, and mood disorder) for studies reporting suicides or suicide attempts during treatment with and without lithium in recurrent MDD patients, and we added data for 78 new subjects, provided from the Lucio Bini Mood Disorders Research Center in Sardinia, Italy. Suicide rates were pooled and analyzed by use of incidence-rate ratios (IRRs) and meta-analytic methods.
Eight studies involved 329 MDD patients and exposure for 4.56 years (1149 person-years) with, and 6.27 years (1285 person-years) without, lithium. Overall risk of suicides and suicide attempts was 88.5% lower with vs. without lithium: 0.17%/y versus 1.48%/y (IRR = 8.71; 95% CI: 2.10 to 77.2, p = .0005); for completed suicides (85% risk reduction), IRR = 6.77 (95% CI: 1.29 to 66.8, p = .01). Meta-analysis by risk difference and risk ratio supported these findings, and sensitivity analysis yielded similar results with studies omitted serially.
This is the first meta-analysis suggesting antisuicidal effects of lithium in recurrent MDD, similar in magnitude to that found in bipolar disorders.

Full-text preview

Available from: fsu.edu
  • Source
    • "However, the first-line of choice antidepressant treatments, including SSRIs, and SNRIs, have drawbacks since it can take weeks to develop beneficial mood-enhancing effects, and the risk for suicidality has been reported to increase during the first weeks of treatment, especially in children and adolescents (Wasserman et al., 2012). Pharmacological treatment with lithium in mood disorders (Baldessarini et al., 2006;Guzzetta et al., 2007), clozapine in schizophrenia (Meltzer and Baldessarini, 2003), and electroconvulsive therapy in treatment-resistant depression (Kennedy et al., 2009) have proven effective in decreasing suicidal behavior. In addition, a robust and rapid (within hours) antidepressant and anti-suicidal effect is produced by intravenous injection of ketamine, which is an NMDA-receptor antagonist (Fond et al., 2014;M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 5 2013). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Suicide is a major global problem, claiming more than 800,000 lives annually. The neurobiological changes that underlie suicidal ideation and behavior are not fully understood. Suicidal patients have been shown to display elevated levels of inflammation both in the central nervous system and the peripheral blood. A growing body of evidence suggests that inflammation is associated with a dysregulation of the kynurenine pathway in suicidal patients, resulting in an imbalance of neuroactive metabolites. Specifically, an increase in the levels of the NMDA receptor agonist quinolinic acid and a simultaneous decrease in neuroprotective metabolites have been observed in suicidal patients, and may contribute to the development of suicidality via changes in glutamate neurotransmission and neuroinflammation. The cause of the dysregulation of kynurenine metabolites in suicidality is not known, but is likely due to differential activity of the involved enzymes in patients. As knowledge in these areas is rapidly growing, targeting the kynurenine pathway enzymes may provide novel therapeutic approaches for managing suicidal behavior.
    Full-text · Article · Jan 2016 · Neuropharmacology
  • Source
    • "Baldessarini et al. (2006) conducted a meta-analysis of 45 studies including more than 33,000 patients showing that patients treated with lithium had a 5-fold reduced risk of suicide or suicide attempts compared to patients treated with other substances. When analyzing data of 328 Sardinian patients with unipolar depression, Guzzetta et al. (2007) found a significant lower risk for suicide attempts and suicides in lithium-treated patients. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The management and treatment of patients with suicidal behavior is one of the most challenging tasks for health-care professionals. Patients with affective disorders are at high risk for suicidal behavior, therefore, should be a target for prevention. Numerous international studies of lithium use have documented anti-suicidal effects since the 1970s. Despite the unambiguous evidence of lithium's anti-suicidal effects and recommendations in national and international guidelines for its use in acute and maintenance therapy of affective disorders, the use of lithium is still underrepresented. The following article provides a comprehensive review of studies investigating the anti-suicidal effect of lithium in patients with affective disorders.
    Full-text · Article · Dec 2015
  • Source
    • "Although over 60 years have elapsed since its effects on mania were first described, lithium (LI) is still a mainstay in the treatment of mood disorders and remains the standard against which new mood-stabilizing or thymoleptic drugs are measured (Price and Heninger 1994). LI treatment paradoxically relieves both mania and depression—conditions that appear to be opposites, and additionally, it has been reported to have specific antisuicidal effects (Baldessarini et al. 2006; Guzzetta et al. 2007). However, the mechanism by which LI effectively treats bipolar disorder (BP) and depression and reduces the risk of suicidal behaviors is largely unknown. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Both valproic acid (VPA) and lithium (LI) are well-established treatments for therapy of intense and sustained mood shifts, which are characteristics of affective disorders, such as bipolar disorder (BP). As mood and cognitive judgment bias have been found to be strongly interrelated, the present study investigated, in an animal model, whether acute treatment with VPA or LI could affect cognitive judgment bias. To accomplish this goal, two groups of rats received single injections of either VPA or LI after initial behavioral training and were subsequently tested with the ambiguous-cue interpretation (ACI) test. Both drugs were administered in three doses using the fully randomized Latin square design. VPA (100, 200, and 400 mg/kg) had no significant effect on the interpretation of the ambiguous cue. LI at the lowest dose (10 mg/kg) had no effect; at an intermediate dose (50 mg/kg), it significantly biased animals towards positive interpretation of the ambiguous cue, and at the highest dose (100 mg/kg), it impaired the ability of animals to complete the test. To our knowledge, this is the first study demonstrating lithium's effects on increased optimistic judgment bias. Future studies may focus on the ability of putative pharmacotherapies to modify the cognitive judgment bias dimension of patients at risk for bipolar disorder or depression.
    Full-text · Article · Dec 2014 · Psychopharmacology
Show more